Plasma thrombin-activatable fibrinolysis inhibitor as an indicator of inflammation and disease severity in acute pancreatitis

Clinics and Research in Hepatology and Gastroenterology

Volumn 36, Issue 5, 2012, Pages 498-504

  Sayilir, Abdurrahim ^a   Beyazit, Yavuz ^a   Yesil, Yusuf ^b   Albayrak, Murat ^c   Ekiz, Fuat ^c   Çelik, Tuĝrul ^d   Suvak, Burak ^a   Torun, Serkan ^a   Ibiş, Mehmet ^a  

^a Turkiye Yuksek Ihtisas Teaching and Research Hospital   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^d ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ACUTE PANCREATITIS; ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COMPUTERIZED TOMOGRAPHY SEVERITY INDEX; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FIBRINOLYSIS; HUMAN; LEUKOCYTE; MALE; MODIFIED GLASGOW PROGNOSTIC SCORE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; REMISSION; SENSITIVITY AND SPECIFICITY; THROMBOCYTE;

ACUTE DISEASE; CARBOXYPEPTIDASE U; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PANCREATITIS; SEVERITY OF ILLNESS INDEX;

EID: 84868348148     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.12.006     Document Type: Article

References (47)

1. Tonsi A.F., Bacchion M., Crippa S., Malleo G., Bassi C. Acute pancreatitis at the beginning of the 21st century: the state of the art. World J Gastroenterol 2009, 28:2945-2959.
2. Saluja A.K., Lerch M.M., Phillips P.A., Dudeja V. Why does pancreatic overstimulation cause pancreatitis?. Annu Rev Physiol 2007, 69:249-269.
3. Bhatia M. Acute pancreatitis as a model of SIRS. Front Biosci 2009, 14:2042-2050.
4. Esmon C.T. The interactions between inflammation and coagulation. Br J Haematol 2005, 131:417-430.
5. Owczarek D., Undas A., Foley J.H., Nesheim M.E., Jablonski K., Mach T. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases: TAFIa level in patients with IBD. J Crohns Colitis 2011, 5. 10.1016/j.crohns.2011.06.00.
6. Lasson A., Ohlsson K. Disseminated intravascular coagulation and antiprotease activity in acute human pancreatitis. Scand J Gastroenterol Suppl 1986, 126:35-39.
7. Tenner S., Sica G., Hughes M., Noordhoek E., Feng S., Zinner M., et al. Relationship of necrosis to organ failure in severe acute pancreatitis. Gastroenterology 1997, 113:899-903.
8. Yasuda T., Ueda T., Kamei K., Shinzaki W., Sawa H., Shinzeki M., et al. Plasma tissue factor pathway inhibitor levels in patients with acute pancreatitis. J Gastroenterol 2009, 44:1071-1079.
9. Foitzik T., Eibl G., Hotz B., Hotz H., Kahrau S., Kasten C., et al. Persistent multiple organ microcirculatory disorders in severe acute pancreatitis: experimental findings and clinical implications. Dig Dis Sci 2002, 47:130-138.
10. Lisman T., Porte R.J. Activation and regulation of hemostasis in acute liver failure and acute pancreatitis. Semin Thromb Hemost 2010, 36:437-443.
11. Bouma B.N., Meijers J.C. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003, 1:1566-1574.
12. Boffa M.B., Nesheim M.E., Koschinsky M.L. Thrombin activable fibrinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders. Curr Drug Targets Cardiovasc Haematol Disord 2001, 1:59-74.
13. Erdogan M., Solmaz S., Canataroglu A., Kulaksizoglu M., Cetinkalp S., Ozgen A.G., et al. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in diabetic foot ulcers. Endocrine 2010, 37:449-454.
14. Bajzar L., Nesheim M.E., Tracy P.B. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996, 88:2093-2100.
15. Kruszynska Y.T., Yu J.G., Olefsky J.M., Sobel B.E. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes 2000, 49:633-639.
16. Hamsten A., de Faire U., Walldius G., Dahlén G., Szamosi A., Landou C., et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987, 2:3-9.
17. Silveira A., Schatteman K., Goossens F., Moor E., Scharpé S., Strömqvist M., et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000, 84:364-368.
18. Donmez A., Aksu K., Celik H.A., Keser G., Cagirgan S., Omay S.B., et al. Thrombin-activatable fibrinolysis inhibitor in Behçet's disease. Thromb Res 2005, 115:287-292.
19. So A.K., Varisco P.A., Kemkes-Matthes B., Herkenne-Morard C., Chobaz-Péclat V., Gerster J.C., et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 2003, 1:2510-2515.
20. Yano Y., Kitagawa N., Gabazza E.C., Morioka K., Urakawa H., Tanaka T., et al. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab 2003, 88:736-741.
21. Leung L.L., Nishimura T., Myles T. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Adv Exp Med Biol 2008, 632:61-69.
22. Bradley E.L. A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg 1993, 128:586-590.
23. Blamey S.L., Imrie C.W., O'Neill J., Gilmour W.H., Carter D.C. Prognostic factors in acute pancreatitis. Gut 1984, 25:1340-1346.
24. Balthazar E.J., Robinson D.L., Megibow A.J., Ranson J.H. Acute pancreatitis: value of CT in establishing prognosis. Radiology 1990, 174:331-336.
25. Abdulla A., Awla D., Hartman H., Rahman M., Jeppsson B., Regnér S., et al. Role of platelets in experimental acute pancreatitis. Br J Surg 2011, 98:93-103.
26. Appelros S., Lindgren S., Borgström A. Short and long term outcome of severe acute pancreatitis. Eur J Surg 2001, 167:281-286.
27. Munsell M.A., Buscaglia J.M. Acute pancreatitis. J Hosp Med 2010, 5:241-250.
28. Peters M.J., Nurmohamed M.T., van Eijk I.C., Verkleij C.J., Marx P.F. Thrombin-activatable fibrinolysis inhibitor and its relation with inflammation in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1232-1233.
29. Myles T., Nishimura T., Yun T.H., Nagashima M., Morser J., Patterson A.J., et al. Thrombin-activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003, 278:51059-51067.
30. Guimarães A.H., Laurens N., Weijers E.M., Koolwijk P., van Hinsbergh V.W., Rijken D.C. TAFI and pancreatic carboxypeptidase B modulate in vitro capillary tube formation by human microvascular endothelial cells. Arterioscler Thromb Vasc Biol 2007, 27:2157-2162.
31. Swaisgood C.M., Schmitt D., Eaton D., Plow E.F. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest 2002, 110:1275-1282.
32. Declerck P.J. Thrombin-activatable fibrinolysis inhibitor. Hamostaseologie 2011, 31:165-173.
33. Coughlin S.R. Thrombin signalling and protease-activated receptors. Nature 2000, 407:258-264.
34. Rooth E., Wallen H., Antovic A., von Arbin M., Kaponides G., Wahlgren N., et al. Thrombin-activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke. Blood Coagul Fibrinolysis 2007, 18:365-370.
35. Saibeni S., Bottasso B., Spina L., Bajetta M., Danese S., Gasbarrini A., et al. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol 2004, 99:1966-1970.
36. Brouns R., Heylen E., Willemse J.L., Sheorajpanday R., De Surgeloose D., Verkerk R., et al. The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome. J Thromb Haemost 2010, 8:75-80.
37. Wu B.U., Johannes R.S., Sun X., Tabak Y., Conwell D.L., Banks P.A. The early prediction of mortality in acute pancreatitis: a large population-based study. Gut 2008, 57:1698-1703.
38. Robert J.H., Frossard J.L., Mermillod B., et al. Early prediction of acute pancreatitis: prospective study comparing computed tomography scans, Ranson, Glascow, Acute Physiology and Chronic Health Evaluation II scores, and various serum markers. World J Surg 2002, 26:612-619.
39. Simchuk E.J., Traverso L.W., Nukui Y., Kozarek R.A. Computed tomography severity index is a predictor of outcomes for severe pancreatitis. Am J Surg 2000, 179:352-355.
40. Maeda K., Hirota M., Ichihara A., Ohmuraya M., Hashimoto D., Sugita H., et al. Applicability of disseminated intravascular coagulation parameters in the assessment of the severity of acute pancreatitis. Pancreas 2006, 32:87-92.
41. Radenkovic D., Bajec D., Ivancevic N., Milic N., Bumbasirevic V., Jeremic V., et al. d-dimer in acute pancreatitis: a new approach for an early assessment of organ failure. Pancreas 2009, 38:655-660.
42. Uhl W., Büchler M., Malfertheiner P., Martini M., Beger H.G. PMN-elastase in comparison with CRP, antiproteases, and LDH as indicators of necrosis in human acute pancreatitis. Pancreas 1991, 6:253-259.
43. Al-Bahrani A.Z., Ammori B.J. Clinical laboratory assessment of acute pancreatitis. Clin Chim Acta 2005, 362:26-48.
44. Imamura T., Tanaka S., Yoshida H., et al. Significance of measurement of high-sensitivity C-reactive protein in acute pancreatitis. Gastroenterol 2002, 37:935-938.
45. Triester S.L., Kowdley K.V. Prognostic factors in acute pancreatitis. J Clin Gastroenterol 2002, 34:167-176.
46. Imamura T., Tanaka S., Yoshida H., Kitamura K., Ikegami A., Takahashi A., et al. Significance of measurement of high-sensitivity C-reactive protein in acute pancreatitis. J Gastroenterol 2002, 37:935-938.
47. Modrau I.S., Floyd A.K., Thorlacius-Ussing O. The clinical value of procalcitonin in early assessment of acute pancreatitis. Am J Gastroenterol 2005, 100:1593-1597.